Lv11
52 积分 2024-03-07 加入
(ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study
2小时前
待确认
Treatment advances across the cervical cancer spectrum
13天前
已完结
Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation
13天前
已完结
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
16天前
已完结
Personalized Primary and Secondary Prevention in Ovarian Cancer
21天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
22天前
已完结
Rethinking ovarian cancer III: the past decade and future directions
22天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
26天前
已完结
The landscape of cancer research and cancer care in China
27天前
已完结
Treatment advances across the cervical cancer spectrum
28天前
已完结
皖公网安备34019202002308
